Clinical Characterization of the PD Profile of a Monoclonal Antibody

ABL successfully validated and implemented a receptor occupancy assay on behalf of a Phase II clinical trial. The pharmacodynamic profile of this monoclonal antibody, established from our high-quality data, when combined with additional PK and efficacy data, proved instrumental in informing decisions on dose selection for the following clinical trials.